

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

11748-006-999

APPLICATION NO.

10/516,759

APPLICANT

Mingdong Zhou

FILING DATE

March 3, 2006

ART UNIT

1642

U.S. PATENT DOCUMENTS

*Examiner Initials	Document Number	Date mm/dd/yy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

*Examiner Initials	Foreign Patent Document Country Code, Number, Kind Code (if known)	Date mm/dd/yy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
	B13	WO 98/17797 A1	04/30/98	Genentech, Inc.	

NON PATENT LITERATURE DOCUMENTS

*Examiner Initials	Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T
C45	BANDYOPADHYAY et al., "Physical interaction between epidermal growth factor receptor and DNA-dependent protein kinase in mammalian cells," J Biol Chem., 1998, 273: 1568-1573	
C46	FARESS et al., "Bleomycin-induced pulmonary fibrosis is attenuated by a monoclonal antibody targeting HER2," J Appl Physiol., 2007 103: 2077-2083	
C47	HUDZIAK et al., "p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor," 1989, Mol Cell Biol., 9: 1165-1172.	
C48	INTERNATIONAL PRELIMINARY EXAMINATION REPORT OF PCT/AU00/00671	
C49	LEVY et al., "Biological and clinical implications of lymphocyte hybridomas: tumor therapy with monoclonal antibodies," Annu Rev Med., 1983, 34: 107-116	
C50	LEWIS et al., "Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies," Cancer Immunol Immunother., 1993, 37: 255-263	
C51	LEWIS et al., "Growth regulation of human breast and ovarian tumor cells by heregulin: Evidence for the requirement of ErbB2 as a critical component in mediating heregulin responsiveness," Cancer Res., 1996, 56: 1457-1465	
C52	SCHROFF et al., "T65 antigen modulation in a phase I monoclonal antibody trial with chronic lymphocytic leukemia patients," J Immunol., 1984, 133: 1641-1648	
C53	STOICA et al., "Effect of estradiol on estrogen receptor-alpha gene expression and activity can be modulated by the ErbB2/PI 3-K/Akt pathway," Oncogene, 2003, 22: 7998-8011.	
C54	VADLAMUDI et al., "Regulation of cyclooxygenase-2 pathway by IHER2 receptor," Oncogene, 1999, 18: 305-314.	
C55	WANG et al., "Reciprocal interactions between beta1-integrin and epidermal growth factor receptor in three-dimensional basement membrane breast cultures: a different perspective in epithelial biology," Proc Natl Acad Sci U S A., 1998, 95: 14821-14826	
C56	XU et al., "Antibody-induced growth inhibition is mediated through immunohistochemically and functionally distinct epitopes on the extracellular domain of the c-erbB-2 (HER-2/neu) gene product p185," Int J Cancer, 1993, 53: 401-408	

EXAMINER

SHI-77649v1

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. A.L.B.G

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	11748-006-999	10/516,759
	APPLICANT	
	Mingdong Zhou	
	FILING DATE	ART UNIT
	March 3, 2006	1642

U.S. PATENT DOCUMENTS

*Examiner Initials	Document Number	Date mm/dd/yy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	C57	YE et al , "Augmentation of a humanized anti-HER2 mAb 4D5 induced growth inhibition by a human-mouse chimeric anti-EGF receptor mAb C225," Oncogene, 1999, 18: 731-738		

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /L.B.G./

EXAMINER SHI-77649v1	/Laura B. Goddard/	DATE CONSIDERED	11/20/2010
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered Include copy of this form with next communication to applicant			